Your browser doesn't support javascript.
loading
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Mulder, Renée L; Font-Gonzalez, Anna; Hudson, Melissa M; van Santen, Hanneke M; Loeffen, Erik A H; Burns, Karen C; Quinn, Gwendolyn P; van Dulmen-den Broeder, Eline; Byrne, Julianne; Haupt, Riccardo; Wallace, W Hamish; van den Heuvel-Eibrink, Marry M; Anazodo, Antoinette; Anderson, Richard A; Barnbrock, Anke; Beck, Joern D; Bos, Annelies M E; Demeestere, Isabelle; Denzer, Christian; Di Iorgi, Natascia; Hoefgen, Holly R; Kebudi, Rejin; Lambalk, Cornelis; Langer, Thorsten; Meacham, Lillian R; Rodriguez-Wallberg, Kenny; Stern, Catharyn; Stutz-Grunder, Eveline; van Dorp, Wendy; Veening, Margreet; Veldkamp, Saskia; van der Meulen, Eline; Constine, Louis S; Kenney, Lisa B; van de Wetering, Marianne D; Kremer, Leontien C M; Levine, Jennifer; Tissing, Wim J E.
Afiliación
  • Mulder RL; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Electronic address: r.l.mulder@prinsesmaximacentrum.nl.
  • Font-Gonzalez A; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Hudson MM; Department of Epidemiology and Cancer Control and Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • van Santen HM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, Netherlands.
  • Loeffen EAH; Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, UMC Groningen, University of Groningen, Groningen, Netherlands.
  • Burns KC; Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Quinn GP; Department of Obstetrics and Gynecology, Department of Population Health, and Division of Medical Ethics, New York University School of Medicine, New York University, New York, NY, USA.
  • van Dulmen-den Broeder E; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Byrne J; Boyne Research Institute, Drogheda, Ireland.
  • Haupt R; Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Wallace WH; Department of Paediatric Haematology and Oncology, Royal Hospital for Sick Children, Edinburgh, UK.
  • van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands.
  • Anazodo A; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
  • Anderson RA; Medical Research Council Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
  • Barnbrock A; Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany.
  • Beck JD; Hospital for Children and Adolescents, University of Erlangen-Nürnberg, Erlangen, Germany; LESS Group, Hospital for Children and Adolescents, University of Lübeck, Lübeck, Germany.
  • Bos AME; Department of Reproductive Medicine and Gynaecology, UMC Utrecht, Utrecht, Netherlands.
  • Demeestere I; Research Laboratory on Human Reproduction and Fertility Clinic, Department of Obstetrics and Gynecology, CUB-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Denzer C; Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
  • Di Iorgi N; Department of Pediatrics, IRCCS Istituto Giannina Gaslini, University of Genova, Genova, Italy.
  • Hoefgen HR; Division of Pediatric and Adolescent Gynecology, Washington University School of Medicine, Washington University, St Louis, MO, USA.
  • Kebudi R; Division of Pediatric Hematology-Oncology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, Istanbul, Turkey; Oncology Institute, Istanbul University, Istanbul, Turkey.
  • Lambalk C; Department of Obstetrics and Gynecology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Langer T; Division Pediatric Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
  • Meacham LR; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA; Division of Hematology/Oncology and Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA, USA.
  • Rodriguez-Wallberg K; Division of Gynecology and Reproduction, Department of Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Stern C; Melbourne IVF, East Melbourne, VIC, Australia; Reproductive Services, Royal Women's Hospital, Melbourne, VIC, Australia.
  • Stutz-Grunder E; Department of Pediatric Oncology, Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • van Dorp W; Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, Netherlands.
  • Veening M; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Veldkamp S; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • van der Meulen E; Dutch Childhood Cancer Parent Organization (VOX), Nieuwegein, Netherlands.
  • Constine LS; Department of Radiation Oncology and Department of Pediatrics, University of Rochester Medical Center, University of Rochester, Rochester, NY, USA.
  • Kenney LB; Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA, USA.
  • van de Wetering MD; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Levine J; Division of Pediatric Hematology and Oncology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  • Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, UMC Groningen, University of Groningen, Groningen, Netherlands.
Lancet Oncol ; 22(2): e45-e56, 2021 02.
Article en En | MEDLINE | ID: mdl-33539753
ABSTRACT
Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Preservación de la Fertilidad / Supervivientes de Cáncer / Neoplasias Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Preservación de la Fertilidad / Supervivientes de Cáncer / Neoplasias Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article